[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353417-105":59,"doc-detail-353417-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-proling-and-access-to-treatment-for-rare-cancers-in-europe","Molecular Proﬁling and Access to Treatment for Rare Cancers in Europe","","Molecular proﬁling and access to treatment for rare cancers in Europe is addressed through the Arcagen clinical study, which analyzes molecular and clinical features of rare adult solid cancers across 11 domains using the EORTC-SPECTA platform within the EURACAN ERN. Among 1235 advanced-stage patients, 893 were evaluable for molecular proﬁling. Actionable mutations were found in 69.4% of patients, and 93 patients received targeted or immune therapies. Survival varied by whether treatment adaptation occurred.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-proling-and-access-to-treatment-for-rare-cancers-in-europe/353417/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-proling-and-access-to-treatment-for-rare-cancers-in-europe/353417.png","ImageObject",300,407,{"name":92,"@type":93},"anakgang17","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the Arcagen study and how was molecular profiling conducted?","Question",{"text":112,"@type":113},"Arcagen is a clinical study assessing molecular and clinical characteristics of rare adult solid cancers across Europe. It uses the EORTC-SPECTA platform within EURACAN to support comprehensive tissue and molecular analyses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many patients were evaluable for molecular profiling, and what fraction had actionable mutations?",{"text":117,"@type":113},"Out of 1235 enrolled advanced-stage patients, 893 were evaluable for molecular profiling. In the 11 domains, 69.4% (620/893) had actionable mutations.",{"name":119,"@type":110,"acceptedAnswer":120},"What impact did treatment adaptation have on overall survival?",{"text":121,"@type":113},"Median overall survival differed depending on whether treatment was adapted to targeted therapy or immunotherapy. Values reported were 1.1 years without adaptation, 3.3 years with switch to targeted therapy, and not reached for immunotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353417,1790535875,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article [https://doi.org/10.1038/s41467-026-75776-1](https://doi.org/10.1038/s41467-026-75776-1)  \nMolecular proﬁling and access to treatment for rare cancers in Europe  \nReceived: 22 January 2026  \n\n| Accepted: 6 July 2026 |\n| --- |\n| |\n| Check for updates |\n\nM. Morfouace 1,2 , F. Hoogstoel 2, J. Oliveira3, N. Penel 4,5, S. Tejpar 6, I. Ray-Coquard 7, J. Peron8, M. Pracht9, B. Brasiuniene10,11, A. Capela 12,  \nC. Gennigens13, L. Greillier14, C. Even15, R. Huang16, T. Gorlia2, G. Lombardi 17, M. Gamulin 18, L. Licitra19, N. Girard20, H. J. Klümpen21, A. Idbaih22, WTA Van der Graaf23,24 & J. Y. Blay 7   \nArcagen is a clinical study proposing a comprehensive analysis of molecular and clinical characteristics of rare adult solid cancers (11 domains: sarcomas, gynecology, uro-genital, GI, NET, head and neck, thoracic, skin and eyes, CNSand CUP) across Europe, utilizing the EORTC-SPECTA platform with the EURACAN ERN. This study enrolled 1235 advanced stage patients. 893 were evaluable for molecular proﬁling toward a potential access to personalized therapy.In the 11 different domains, 69.4%(620/893) of patients had actionable mutations, among whom 93 (15% of 620 patients with currently actionable alterations) received targeted-or immune (IO)-therapies. The median overall survival of the patient population without treatment adaptation, with switch to targeted therapy, or immunotherapy was 1.1, 3.3 years, and not reached, respectively.Across Europe, high prevalence and diversity of molecular alterations for rare solid tumors were observed as well as signiﬁcant disparities regarding access to personalized medicine approaches.  \nRare cancers are deﬁned by an annual incidence \u003C6 per 100,000 people1. While individual rare cancer are low incidence, when combined, they correspond to 22%(~650,000 new diagnoses annually) of overall cancer incidence and cause over 30% of cancer mortality in the EU1. It is estimated that 5.1 million people live with a rare cancer in  \nEurope. In 2017, 4 European reference networks (ERN) were launched to address the challenges of rare cancer (including hereditary syndromes) management with the aim to improve patient pathways, diagnosis, care, and dedicated research2. EURACAN is the ERN dedicated to rare adult solid cancers.  \n1Institut Gustave Roussy, Direction de la Recherche Clinique, Villejuif, France. 2European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium. 3Instituto Portugues de Oncologia do Porto Francisco Gentil, Porto, Portugal. 4Department of Medical Oncology, Centre Oscar-Lambret, University of Lille, Lille, France. 5ULR 2694-Metrics: Evaluation des technologies de santé et des pratiques médicales, CHU of Lille, University of Lille, Lille, France. 6UZ Leuven, Leuven, Belgium. 7Centre Leon Berard, University Claude Bernard Lyon 1, Lyon, France. 8Department of Medical Oncology, Hospices Civils de Lyon, RESHAPE laboratory, Lyon, France. 9Centre Eugene Marquis, Department of Clinical Oncology, Rennes, France. 10National Cancer Center of Vilnius University hospital Santaros clinic, Vilnius, Lithuania. 11Faculty of Medicine of Vilnius University, Vilnius, Lithuania. 12Unidade Local de Saúde de Gaia e Espinho, Vila Nova de Gaia, Portugal. 13Department of Medical Oncology, University Hospital of Liège, CHU of Liège, Liège, Belgium. 14Aix-Marseille Univ, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseille, France. 15Head and Neck Department, Gustave Roussy, Villejuif, France. 16Foundation Medicine Inc., Boston, Massachusetts, USA. 17Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy. 18University of Zagreb, School of Medicine Department of Clinical Oncology, University Hospital Centre Zagreb, Department of Oncology, Zagreb, Croatia. 19Istituto Tumori, Milan, Italy. 20Institut Curie, Paris, France. 21University Medical Center Groningen, Department of Medical Oncology, Groningen, The Netherlands. 22Sorbonne Université, AP-HP, Institut du C","cbCaireqMfxJC3QT","https://ap.wps.com/l/cbCaireqMfxJC3QT","pdf",1494379,12,"English","# Results Study cohort\n## Molecular proﬁling and actionable mutations\n## Treatment adaptation and survival outcomes\n# Access disparities and study rationale\n## Definition and burden of rare cancers in Europe\n## EURACAN and the Arcagen study purpose","[{\"question\":\"What is the Arcagen study and how was molecular profiling conducted?\",\"answer\":\"Arcagen is a clinical study assessing molecular and clinical characteristics of rare adult solid cancers across Europe. It uses the EORTC-SPECTA platform within EURACAN to support comprehensive tissue and molecular analyses.\"},{\"question\":\"How many patients were evaluable for molecular profiling, and what fraction had actionable mutations?\",\"answer\":\"Out of 1235 enrolled advanced-stage patients, 893 were evaluable for molecular profiling. In the 11 domains, 69.4% (620/893) had actionable mutations.\"},{\"question\":\"What impact did treatment adaptation have on overall survival?\",\"answer\":\"Median overall survival differed depending on whether treatment was adapted to targeted therapy or immunotherapy. Values reported were 1.1 years without adaptation, 3.3 years with switch to targeted therapy, and not reached for immunotherapy.\"}]","Molecular Proﬁling and Access to Treatment for Rare Cancers in Europe | PDF",1790105205,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2fd14584fcb70a1fc47af4de5f699a7e.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86455512625019bfe57b5ffe7af46c6f.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e886307df89ddfa3d0469f024b79ff9.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8bafe4797002bb2fe4b30148c6cfea4c.webp",980,1301]